retatrutide clinical trials obesity ESC 2024: improves lipid and cardiovascular risk profile in Phase II trial New GLP-1 obesity drug, retatrutide,

Furthermore, long-term fracture risk, bone microarchitecture changes, and implant survival in GLP-1 agonist users remain poorly studied

A timeline of legal events involving weight-loss drugs (Schuduled) May 2025 - On May 14, 2025, a pivotal Rule 702 evidentiary hearing is scheduled to take place

Theres no reason to believe that the increased mitochondrial biogenesis, the activation of mitochondrial proteins, the antioxidant enzyme production are not happening to some degree, even with the smallest levels of GLP-1s, he says

4 Food noise quietens for the same reason

This gradual increase helps the body adapt to GLP-1, GIP, and glucagon activation simultaneously

The conclusion: marketing claims substantially exceeded the available evidence